A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ELARIS EM-II; EM-II; Solstice
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Jul 2018 According to AbbVie media release, AbbVie Receives U.S. FDA Approval of ORILISSA for the Management of Moderate to Severe Pain Associated with Endometriosis.
    • 23 May 2018 Results from ELARIS EM-I and EM-II studies, presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 23 May 2018 Results assessing effect of elagolix on health-related quality of life outcome presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top